Jazz Pharmaceuticals (JAZZ) Stock: Buy, Sell, or Hold?
$245.43
+1.89 (+0.77%)
▲
5d:
+6.83%
30d:
+13.23%
90d:
-1.41%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 02, 2026
0d
Protect JAZZ Gains
Updated Nov 10, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (39%)
Quality Score
43/100
Position
EXTENDED
30-Day Fair Range
$208.05 – $231.58
Position: EXTENDED
Forward P/E & Valuation
9.4x
FAIR
vs 8.5x historical avg
Wall Street Target
$296.27
+20.7% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$202.30 / $246.47
Trend: Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: JAZZ shows conflicting indicators. Wait for confirmation before entering.
Get Alerted When JAZZ Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$430.17
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$267.10
8.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: JAZZ is currently trading at $245.43, which is considered extended relative to its 30-day fair value range of $208.05 to $231.58. From a valuation perspective, the stock is trading at a premium (Forward PE: 9.4) compared to its historical average (8.5). At these levels, the market is pricing in 3.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, JAZZ is in a downtrend. The price is approaching resistance at $246.47. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: JAZZ scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $296.27 (+20.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, JAZZ is in a downtrend. The price is approaching resistance at $246.47. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: JAZZ scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $296.27 (+20.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$208.05 -
$231.58
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
39.2%
Trading Range & Key Levels
30-Day Trading Range
$208.05 -
$231.58
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$9.29
(3.8%)
Support Level
$202.30
Resistance Level
$246.47
Current Trend
Downtrend
Technical data as of
Nov 10, 2026
Protect Your Profits
Holding JAZZ? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- BEARISH: Price extended above range (+6.0% above its trading range)
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 20.7% below Wall St target ($296.27)
- NEUTRAL: Market pricing in 3.6% annual earnings growth - fairly valued
- WARNING: Composite score 43/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
9.44
Wall Street Target
$296.27
(+20.7%)
Revenue Growth (YoY)
10.4%
Earnings Growth (YoY)
3.2%
Profit Margin
4.4%
Valuation Premium vs History
+3.6% premium
PE vs Historical
9.4 vs 8.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.6%
(market-implied from PE analysis)
1-Year Target
$254.27
(+4%)
2-Year Target
$263.42
(+7%)
3-Year Target
$272.90
(+11%)
3-Yr Target (if PE normalizes)
(PE: 9→9)
PE COMPRESSION
$245.63
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 73.9%)
$1741.92
(+610%)
Base:
(SPY PE: 9.4, Growth: 73.9%)
$828.33
(+238%)
Bear:
(PE: 8.0, Growth: 73.9%)
$704.08
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (10x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Forward PE: 10.04 | Forward EPS (Implied): $24.44
Bull Case
$296.36
(+21%)
Analyst growth 15.0%, PE expands to 10.5
Base Case
$245.43
(0%)
Market implied 0.0%, PE stable at 10.0
Bear Case
$187.75
(-24%)
Severe decline -15.0%, PE contracts to 9.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share JAZZ Analysis
Share this live JAZZ analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (JAZZ)
Bullish
3 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
2 msgs
24h retail stream
Last Tracked
Nov 3, 2026
Daily AI digest
AI Retail Discussion Summary:
Jazz Pharmaceuticals (JAZZ) reported Q3 earnings, beating EPS estimates with a smaller loss and surpassing revenue estimates. The company has topped consensus estimates for both earnings and revenue in the last four quarters.
Key Retail Themes:
Positive earnings report
Beat on both EPS and revenue
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 8:04 AM ET
Data refreshes hourly during market hours. Next update: 9:04 AM
Data refreshes hourly during market hours. Next update: 9:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JAZZ showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
25 analysts |
$261 | 52 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
STRONG BUY
25 analysts |
$84 | 45 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
21 analysts |
$95 | 42 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
16 analysts |
$107 | 49 HOLD |
Advanced JAZZ Option Strategies
Professional options setups generated by AI based on today's JAZZ price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive JAZZ Research Pages
